




PHARMACEUTICAL 2021

CytoDyn Inc.
Rank 363 of 402





PHARMACEUTICAL 2021

CytoDyn Inc.
Rank 363 of 402



The relative strengths and weaknesses of CytoDyn Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CytoDyn Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 37% points. The greatest weakness of CytoDyn Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 178% points.

The company's Economic Capital Ratio, given in the ranking table, is -249%, being 296% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	36,827
Cost of Goods Sold	0
Intangible Assets	13,456
Liabilities, Current	44,501
Liabilities, Non-Current	8,494
Other Assets	176
Other Compr. Net Income	0
Other Expenses	20,254
Other Liabilities	0
Other Net Income	-32,036
Other Revenues	500
Property and Equipment	55
Research and Development	52,640
Selling, General and Administrative Expense	19,973

Output Variable	Value in 1000 USD
Assets	50,514
Liabilities	52,995
Expenses	92,867
Revenues	500
Stockholders Equity	-2,480
Net Income	-124,403
Comprehensive Net Income	-124,403
Economic Capital Ratio	-249%